Other than ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and in good shape sufficient to tolerate FCR therapy, may still be very good candidates to the latter, Using the advantage currently being that this treatment is usually accomplished in six months whilst ibrutinib have to be taken indefinitely. This selection will be especiall